Xencor | XNCR - Operating Expenses


Xencor reported $68.52M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Cytokinetics USD 168.69M 9.58M Sep/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
J&J USD 18.97B 2.38B Dec/2025
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
MacroGenics USD 67M 8M Sep/2025
Merck USD 10.16B 558M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Xencor USD 68.52M 8.26M Sep/2025